This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
The trial will run in emergency depatments in NHS secondary and tertiary hospitals in the UK, a total of 308 participants will be recruited and total study duration for each participant will be 24 hours. The Consent study will run alongside EcLiPSE and will involve parents who have been approached about the study and EcLiPSE recruiters. The study will examine approaches to recruitment and deferred consent and explore the views of parents with the aim of identifying recruitment and consent issues and potential solutions to inform EcLiPSE recruiter training materials.
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)